Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04058756 · ClinicalTrials.gov registry record · Phase 1
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
A Phase 1 study of Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT04058756: Active Phase 1 study of Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
NCT04058756 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 120 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04058756, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
Primary Outcome
Safety data.
Conditions Studied
Interventions
- DRUG PDR001
Study Locations (20)
Other
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Liège
- Novartis Investigative Site - Guangzhou
- Novartis Investigative Site - Brno
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Lyon
- Novartis Investigative Site - Marseille
- Novartis Investigative Site - Marseille
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Essen
- Novartis Investigative Site - Heidelberg
- Novartis Investigative Site - Ulm
- Novartis Investigative Site - High West
New York
- Columbia University Medical Center - New York
Oregon
- Providence Portland Medical Center - Portland
Texas
- MD Anderson Cancer Center Uni of Te - Houston
Ontario
- Novartis Investigative Site - Toronto
Quebec
- Novartis Investigative Site - Montreal
Guangdong
- Novartis Investigative Site - Guangzhou
Thuringia
- Novartis Investigative Site - Jena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
What the registry record for NCT04058756 still lists
NCT04058756 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PDR001 is the first listed.
NCT04058756 names 20 study sites across 8 states, led by Other, New York, Oregon.
Frequently Asked Questions
What is clinical trial NCT04058756 about?
NCT04058756 is a clinical study titled "Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments". The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
What is the current status of trial NCT04058756?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2019-10-30. Estimated completion is 2030-04-30.
What conditions does trial NCT04058756 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT04058756?
The interventions under investigation include: PDR001 (DRUG).
Who is sponsoring clinical trial NCT04058756?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04058756 being conducted?
This trial has 20 study locations across New York, Oregon, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04058756's enrollment target sits among peer trials
120 71st of 144 higher than 72 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI